share_log

United Health Products Announces Equity Financing Agreement and Provides Corporate Update

United Health Products Announces Equity Financing Agreement and Provides Corporate Update

联合健康产品宣布股权融资协议并提供企业最新情况
GlobeNewswire ·  2022/09/06 22:15

Mesquite, NV, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- United Health Products, Inc. (OTCPK: UEEC), (UHP) today announced that it has entered into a common stock purchase agreement to sell up to $10 million of shares to White Lion Capital, LLC (White Lion), a California-based institutional investor. Under the terms of the purchase agreement, UHP will have the right, in its sole discretion, to sell shares to White Lion over a 36-month term. Any common stock sold to White Lion will occur at a purchase price derived from the prevailing market prices of the company's common stock at the time of each sale. The company will control the timing and amount of any shares of common stock sold to White Lion, and White Lion is obligated to make purchases at quantities and prices in accordance with the purchase agreement when requested. UHP's ability to make common stock purchase requests is subject to customary limitations and conditions in the stock purchase agreement, including the registration of the resale of the shares on behalf of White Lion under a registration statement to be filed with the SEC on Form S-3.

内华达州梅斯基特,2022年9月6日(GLOBE NEWSWIRE)——通过NewMediaWire——联合健康产品公司(OTCPK:UEEC)(UHP)今天宣布,它已签订普通股购买协议,向总部位于加利福尼亚的机构投资者白狮资本有限责任公司(White Lion)出售高达1000万美元的股票。根据收购协议的条款,UHP将有权自行决定在36个月的期限内向White Lion出售股票。出售给White Lion的任何普通股的购买价格都将根据每次出售时公司普通股的现行市场价格产生。公司将控制向White Lion出售任何普通股的时间和数量,White Lion有义务在收到要求时根据购买协议以数量和价格进行购买。UHP提出普通股购买申请的能力受股票购买协议中的惯例限制和条件的约束,包括根据S-3表格向美国证券交易委员会提交的注册声明代表White Lion登记转售股票。

Separately, the previously announced payments of approximately $1 million to be received by UHP from a former executive of the company have been modified such that the company has received approximately $200,000 and 2,000,000 shares of its common stock are being returned to the company. These shares will be available for reissuance under the above agreement with White Lion.

另外,UHP先前宣布的从该公司前高管那里收到的约100万美元的款项已经修改,使该公司已收到约20万美元,其2,000,000股普通股将归还给该公司。根据与White Lion达成的上述协议,这些股票可以重新发行。

The proceeds of any sale of common stock to White Lion will be used for general corporate purposes including the establishment of a manufacturing operation for the company's HemoStyp hemostatic gauze product and the completion of all remaining elements of the FDA Premarket Approval application, and to advance the development of powder and gel formats of the company's patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent.

向White Lion出售普通股的收益将用于一般公司用途,包括建立该公司的HemoStyp止血纱布产品的制造业务和完成美国食品药品管理局上市前批准申请的所有剩余内容,以及推进该公司获得专利的中和氧化再生纤维素(NORC)止血剂的粉末和凝胶格式的开发。

Regarding the company's previously disclosed legal action relating to the audit of its 2017 financial statements, on August 31, 2022 the company and the defendant entered into a settlement agreement under which, among other provisions, UHP will receive a cash payment this month. 

关于该公司先前披露的与其2017年财务报表审计有关的法律行动,公司与被告于2022年8月31日签订了一项和解协议,根据该协议,除其他条款外,UHP将在本月获得现金付款。

Brian Thom, UHP's Chief Executive Officer, commented: "The resolution of this outstanding litigation, combined with the White Lion transaction and the settlement of payments from our former executive, will provide the company with over $1 million in capital to advance its business plan without diluting shareholders."

UHP首席执行官布莱恩·汤姆评论说:“这起未决诉讼的解决,加上白狮交易和我们前高管的款项结算,将为公司提供超过100万美元的资本,用于在不稀释股东的情况下推进其业务计划。”

Regarding the company's FDA PMA application process, UHP continues to work with its intended manufacturing partner and its regulatory consultant, Regulatory Compliance Associates, to establish production and complete all necessary documentation. UHP is auditing the production facility as well as its documentation and employee training processes, among other elements of the partner's operations. The company's manufacturing equipment will commence production, allowing for the completion of Standard Operating Procedure and Design Control documentation, and the development of the Design Transfer process that will transfer detailed product design information to the manufacturing partner. It is anticipated that the completion of the audit process, establishment and inspection of gauze production, drafting of associated documentation, and testing of product to ensure conformance with previous product specifications will be completed within 60 days. In the interim, the company will continue to provide updates on achievement of milestones in this process.   

关于该公司的FDA PMA申请流程,UHP继续与其预期的制造合作伙伴及其监管顾问Regular Compliance Associates合作,建立生产并完成所有必要的文件。UHP 正在对生产设施及其文档和员工培训流程以及合作伙伴运营的其他内容进行审计。该公司的制造设备将开始生产,从而完成标准操作程序和设计控制文档,并制定设计转移流程,将详细的产品设计信息传送给制造合作伙伴。预计将在60天内完成审计过程、建立和检查纱布生产、起草相关文件以及测试产品以确保符合先前产品规格。在此期间,公司将继续提供有关该过程中实现里程碑的最新情况。

There can be no assurance that the company's PMA application will be approved.

无法保证该公司的PMA申请会获得批准。

Investor relations:
info@unitedhealthproductsinc.com
475.755.1005

投资者关系:
info@unitedhealthproductsinc.com
475.755.1005

Philippe Niemetz
212 344-6464
p.niemetz@panconsultants.com

菲利普·尼梅兹
212 344-6464
p.niemetz@panconsultants.com

About United Health Products -- United Health Products develops, manufactures and markets HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and consumer markets, and is focused on gaining approval to access the human surgical market. 

关于联合健康产品— United Health Products 开发、制造和销售 HemoStyp™,这是一种获得专利的中和氧化再生纤维素 (NORC) 止血剂。HemoStyp 是一种全天然产品,旨在控制出血。UHP目前为牙科、兽医和消费市场提供一套止血产品,并专注于获得进入人体外科市场的批准。

For more information on UHP visit:  or contact the company at info@unitedhealthproductsinc.com

有关 UHP 的更多信息,请访问:或通过 info@unitedhealthproductsinc.com 联系该公司

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

1995年《私人证券诉讼改革法》下的安全港声明:本新闻稿可能包含经修订的1933年《证券法》第27A条和经修订的1934年《证券交易法》第21E条所指的前瞻性信息,包括包含 “相信”、“期望”、“预期” 或类似表达方式的声明。此类前瞻性陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致公司的实际业绩、业绩或成就与此类前瞻性陈述所表达或暗示的业绩、业绩或成就存在重大差异。


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发